Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NAMS
stocks logo

NAMS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.81M
-77.98%
-0.401
-57.71%
0.00
-100%
-0.446
+31.76%
0.00
-100%
-0.449
+199.13%
Estimates Revision
The market is revising Downward the revenue expectations for NewAmsterdam Pharma Company N.V. (NAMS) for FY2025, with the revenue forecasts being adjusted by -14.52% over the past three months. During the same period, the stock price has changed by 32.78%.
Revenue Estimates for FY2025
Revise Downward
down Image
-14.52%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+10.07%
In Past 3 Month
Stock Price
Go Up
up Image
+32.78%
In Past 3 Month
Wall Street analysts forecast NAMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAMS is 46.38 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast NAMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAMS is 46.38 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 35.850
sliders
Low
30.00
Averages
46.38
High
60.00
Current: 35.850
sliders
Low
30.00
Averages
46.38
High
60.00
H.C. Wainwright
Joseph Pantginis
initiated
$52
2025-10-20
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$52
2025-10-20
initiated
Reason
H.C. Wainwright analyst Joseph Pantginis assumed coverage of NewAmsterdam Pharma with a Buy rating and $52 price target. NewAmsterdam is a late clinical-stage biopharmaceutical company developing obicetrapib, a non-statin, next-generation cholesterol ester transfer protein small molecule inhibitor for low-density lipoprotein cholesterol reduction, the analyst tells investors in a research note. The firm says obicetrapib is :poised to burst into the lipid-lowering space."
Citi
Buy
upgrade
$42 -> $50
2025-10-17
Reason
Citi
Price Target
$42 -> $50
2025-10-17
upgrade
Buy
Reason
Citi raised the firm's price target on NewAmsterdam Pharma to $50 from $42 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.
Wells Fargo
Overweight
initiated
$45
2025-08-25
Reason
Wells Fargo
Price Target
$45
2025-08-25
initiated
Overweight
Reason
Wells Fargo initiated coverage of NewAmsterdam Pharma with an Overweight rating and $45 price target. The firm believes cholesteryl ester transfer protein inhibition represents an "exciting new frontier" for lipid lowering and a multibillion dollar opportunity. NewAmsterdam has built obicetrapib on the foundations of four prior CETP inhibitors in the industry and the ongoing PREVAIL study is set up for success, the analyst tells investors in a research note.
Goldman Sachs
Neutral
initiated
$27
2025-07-17
Reason
Goldman Sachs
Price Target
$27
2025-07-17
initiated
Neutral
Reason
Goldman Sachs initiated coverage of NewAmsterdam Pharma with a Neutral rating and $27 price target. The firm sees the stock as range-bound with results from the Phase 3 PREVAIL cardiovascular outcomes trial for the company's lead candidate obicetrapib is not expected until late 2026. However, Goldman is "constructive" on obicetrapib's LDL-C lowering and other lipid effects.
Citi
initiated
$42
2025-06-18
Reason
Citi
Price Target
$42
2025-06-18
initiated
Reason
Stifel
initiated
$44
2025-06-09
Reason
Stifel
Price Target
$44
2025-06-09
initiated
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for NewAmsterdam Pharma Company NV (NAMS.O) is -20.08, compared to its 5-year average forward P/E of 1.49. For a more detailed relative valuation and DCF analysis to assess NewAmsterdam Pharma Company NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
1.49
Current PE
-20.08
Overvalued PE
32.95
Undervalued PE
-29.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
1.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
10.46
Undervalued EV/EBITDA
-7.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
229.98
Current PS
0.00
Overvalued PS
574.25
Undervalued PS
-114.29
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 317.27% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 317.27% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NAMS News & Events

Events Timeline

(ET)
2025-11-05
08:03:53
NewAmsterdam Pharma announces Q3 revenue of $348,000, falling short of consensus estimate of $4.56M.
select
2025-08-18 (ET)
2025-08-18
08:15:15
NewAmsterdam reveals EMA's acceptance of MAA review for obicetrapib
select
2025-08-06 (ET)
2025-08-06
07:05:26
NewAmsterdam Pharma reports Q2 revenue $19.145M vs $2.279M last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
10-20Benzinga
HC Wainwright & Co. Initiates Coverage on NewAmsterdam Pharma Co with a Buy Rating and Sets Price Target at $52

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.

[object Object]
Preview
2.0
09-15NASDAQ.COM
Biotech and Medtech Stocks Surge in After-Hours Trading for Major Companies

  • Surge in Healthcare Stocks: On September 12, several healthcare and biotech stocks, including Penumbra, Check-Cap, Adaptimmune Therapeutics, and NewAmsterdam Pharma, saw significant after-hours trading gains, driven by strategic announcements and clinical milestones, despite some movements occurring without direct news.

  • Penumbra's Stock Performance: Penumbra Inc. experienced a rebound in after-hours trading, rising 6.28% to $289.86, following a decline during regular hours. The company raised its full-year revenue guidance and appointed a new president, indicating confidence in its growth trajectory.

  • Check-Cap's Merger Announcement: Check-Cap Ltd. saw its stock soar by 191.22% after announcing a merger with MBody AI, which aims to enhance its colorectal cancer screening technology with AI capabilities, potentially transforming its strategic direction.

  • NewAmsterdam Pharma's Regulatory Progress: NewAmsterdam Pharma's shares rose 8.23% after-hours, driven by positive investor sentiment regarding its lead candidate obicetrapib and recent regulatory milestones, including accepted Marketing Authorization Applications by the EMA and promising trial data related to Alzheimer's disease biomarkers.

[object Object]
Preview
1.0
09-04Newsfilter
NewAmsterdam Pharma Company N.V. (NAMS) Shares Insights at Citi's Biopharma Back to School Conference Transcript

  • Conference Overview: NewAmsterdam Pharma participated in the Citi's Biopharma Back to School Conference, highlighting their recent achievements and ongoing projects in the biopharmaceutical sector.

  • Phase III Data Highlights: CEO Michael Davidson discussed the successful Phase III BROADWAY trial, which demonstrated significant LDL lowering and a 21% reduction in major adverse cardiovascular events (MACE), alongside recent publications in prestigious medical journals.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is NewAmsterdam Pharma Company NV (NAMS) stock price today?

The current price of NAMS is 35.85 USD — it has increased 0.93 % in the last trading day.

arrow icon

What is NewAmsterdam Pharma Company NV (NAMS)'s business?

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

arrow icon

What is the price predicton of NAMS Stock?

Wall Street analysts forecast NAMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAMS is 46.38 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is NewAmsterdam Pharma Company NV (NAMS)'s revenue for the last quarter?

NewAmsterdam Pharma Company NV revenue for the last quarter amounts to 348.00K USD, decreased -98.80 % YoY.

arrow icon

What is NewAmsterdam Pharma Company NV (NAMS)'s earnings per share (EPS) for the last quarter?

NewAmsterdam Pharma Company NV. EPS for the last quarter amounts to -0.61 USD, increased 238.89 % YoY.

arrow icon

What changes have occurred in the market's expectations for NewAmsterdam Pharma Company NV (NAMS)'s fundamentals?

The market is revising Downward the revenue expectations for NewAmsterdam Pharma Company N.V. (NAMS) for FY2025, with the revenue forecasts being adjusted by -14.52% over the past three months. During the same period, the stock price has changed by 32.78%.
arrow icon

How many employees does NewAmsterdam Pharma Company NV (NAMS). have?

NewAmsterdam Pharma Company NV (NAMS) has 68 emplpoyees as of December 05 2025.

arrow icon

What is NewAmsterdam Pharma Company NV (NAMS) market cap?

Today NAMS has the market capitalization of 4.07B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free